Deakin University
Browse

File(s) not publicly available

Anti-tumour necrosis factor-α therapy for severe enteropathy in patients with common variable immunodeficiency (CVID)

journal contribution
posted on 2007-01-01, 00:00 authored by I Chua, Richard StandishRichard Standish, S Lear, M Harbord, E Eren, M Raeiszadeh, S Workman, D Webster
We present three common variable immunodeficiency (CVID) patients with
severe inflammatory bowel disease of unknown aetiology, resistant to steroid
treatment, treated with infliximab.After exclusion of any infection, infliximab
was given at a dose of 5 mg/kg every 4 weeks for a 3 month induction followed
by every 4–8 weeks depending on clinical response. Two of these patients had
predominantly small bowel disease; they both showed clinical response to
infliximab with weight gain and improvement of quality of life scores. The
third patient had large bowel involvement with profuse watery diarrhea; this
patient improved dramatically within 48 hours of having infliximab
treatment. All three patients have been maintained on infliximab treatment
for between 5 and 53 months (mean 37 months) with no evidence of increased
susceptibility to infections in the patients with small bowel disease, although
the third patient developed two urinary tract infections and a herpes zoster
infection following therapy. This is the first small case series to show that
infliximab is a useful addition to current therapy in this rare group of patients
with potentially life threatening enteritis.

History

Journal

Clinical and experimental immunology

Volume

150

Issue

2

Pagination

306 - 311

Publisher

Wiley - Blackwell

Location

Oxford, England

ISSN

0009-9104

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

2007, British Society for Immunology

Usage metrics

    Research Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC